SG11201908391XA - Methods for modulating an immune response - Google Patents

Methods for modulating an immune response

Info

Publication number
SG11201908391XA
SG11201908391XA SG11201908391XA SG11201908391XA SG 11201908391X A SG11201908391X A SG 11201908391XA SG 11201908391X A SG11201908391X A SG 11201908391XA SG 11201908391X A SG11201908391X A SG 11201908391XA
Authority
SG
Singapore
Prior art keywords
international
present disclosure
disclosure provides
provides methods
kendall
Prior art date
Application number
Other languages
English (en)
Inventor
Seidel, Iii
Rodolfo J Chaparro
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of SG11201908391XA publication Critical patent/SG11201908391XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201908391X 2017-03-15 2018-03-14 Methods for modulating an immune response SG11201908391XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471832P 2017-03-15 2017-03-15
US201762521009P 2017-06-16 2017-06-16
PCT/US2018/022492 WO2018170168A1 (en) 2017-03-15 2018-03-14 Methods for modulating an immune response

Publications (1)

Publication Number Publication Date
SG11201908391XA true SG11201908391XA (en) 2019-10-30

Family

ID=63523265

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908391X SG11201908391XA (en) 2017-03-15 2018-03-14 Methods for modulating an immune response

Country Status (12)

Country Link
US (10) US20200010528A1 (enExample)
EP (2) EP3596118B1 (enExample)
JP (3) JP7717440B2 (enExample)
KR (2) KR20240005989A (enExample)
CN (2) CN111010875B (enExample)
AU (2) AU2018234628B2 (enExample)
CA (1) CA3054955A1 (enExample)
ES (1) ES2989063T3 (enExample)
IL (2) IL269000B2 (enExample)
PH (1) PH12019502076A1 (enExample)
SG (1) SG11201908391XA (enExample)
WO (1) WO2018170168A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10580122B2 (en) 2015-04-14 2020-03-03 Chongqing University Of Ports And Telecommunications Method and system for image enhancement
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
KR20190019068A (ko) * 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7252526B2 (ja) * 2017-01-23 2023-04-05 スチョー アルファマブ カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチド又は化合物
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3737689A4 (en) * 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CN112334153A (zh) 2018-06-20 2021-02-05 丹麦技术大学 用于免疫细胞操作的具有稳定的mhc分子的支架
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途
EP3935080A4 (en) * 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
MX2021014476A (es) * 2019-05-29 2022-02-11 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2021007434A1 (en) * 2019-07-09 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Modulator of antigen specific t cell (modastc) molecules and uses thereof
KR20220066075A (ko) * 2019-09-20 2022-05-23 큐 바이오파마, 인크. T-세포 조절 폴리펩타이드 및 이의 사용 방법
WO2021081239A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. T-cell modulatory chimeric molecules and methods of use thereof
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
WO2021127495A1 (en) * 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US20230293630A1 (en) * 2020-02-12 2023-09-21 La Jolla Institute For Immunology Coronavirus T Cell Epitopes and Uses Thereof
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN115176015A (zh) * 2020-02-28 2022-10-11 国立大学法人金泽大学 免疫调节法、免疫调节用核酸组合物及其用途
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
US20230201335A1 (en) * 2020-05-26 2023-06-29 Cue Biopharma, Inc. Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
AU2021309842A1 (en) * 2020-07-14 2023-02-16 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CA3208643A1 (en) * 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
KR20240024829A (ko) 2021-05-19 2024-02-26 애셔 바이오테라퓨틱스, 인크. Il-21 폴리펩타이드 및 표적화된 작제물
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN120379692A (zh) * 2022-09-30 2025-07-25 弗特附属公司 抗cd122抗体及其用途
WO2025059162A1 (en) * 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025207816A1 (en) * 2024-03-27 2025-10-02 Cue Biopharma, Inc. Treatment of b-cell mediated immune disorders by t-cell mediated depletion of b cells, plasmablasts and plasma cells

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US6218363B1 (en) 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
DE69836209D1 (de) 1997-02-13 2006-11-30 Univ California Vorbeugung und behandlunhg des hepatozellulären krebses
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
ATE491465T1 (de) 1997-05-08 2011-01-15 Oncothyreon Inc Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US7446189B1 (en) 1999-04-30 2008-11-04 Institut De Recherches Cliniques De Montreal Nucleic acids encoding mutant human CD80 and compositions comprising the same
US20020006664A1 (en) 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CA2410642A1 (en) 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US6800748B2 (en) 2001-01-25 2004-10-05 Large Scale Biology Corporation Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
WO2002072631A2 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
WO2002093129A2 (en) 2001-05-15 2002-11-21 University Of Medicine & Dentistry Of New Jersey Methods for analyzing interactions between proteins in live and intact cells
WO2002099089A1 (en) 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
EP1497426A2 (en) 2001-06-22 2005-01-19 Maxygen, Inc. Co-stimulatory molecules
WO2003006632A2 (en) 2001-07-12 2003-01-23 Canvac Methods and compisitions for activation human t cells in vitro
US20040038349A1 (en) 2001-07-27 2004-02-26 Hilbert David M. Heteromultimeric TNF ligand family members
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
CA2479212A1 (en) 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
ATE466085T1 (de) 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
CA2516832A1 (en) 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
AU2003901876A0 (en) 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
EP2783699A1 (en) 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
CA2557677A1 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
CA2567814C (en) 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
BRPI0618449A2 (pt) 2005-11-10 2011-08-30 Receptor Biologix Inc métodos para produção de isoformas de receptor e ligante
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
AU2007254167B2 (en) 2006-05-19 2012-11-15 Technion Research And Development Foundation Ltd. Fusion proteins, uses thereof and processes for producing same
EP1889851A1 (en) 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
EP2980219B1 (en) 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
ES2527412T3 (es) 2007-02-15 2015-01-23 Mannkind Corporation Método para aumentar la respuesta de los linfocitos T
WO2008113970A2 (en) 2007-03-16 2008-09-25 Ucl Business Plc Peptides
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
US8926961B2 (en) 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101418309B (zh) 2007-10-23 2011-05-04 中国农业科学院上海兽医研究所 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US9695410B2 (en) 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
EP4385570A3 (en) 2010-09-21 2024-09-11 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2012274127B2 (en) 2011-06-22 2017-06-22 F. Hoffmann-La Roche Ag Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
EP3357511B1 (en) 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
DE112011100879A5 (de) 2011-08-30 2013-11-14 Jacobs University Bremen Ggmbh Gen codiert für ein MHC-Klasse-I-Molekül, Plasmid, Expressionssystem, Protein, Multimer, Reagenz und Kit zum Analysieren einer T-Zellen-Frequenz
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP2809345A4 (en) 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2925780B1 (en) 2012-11-30 2017-10-18 Roche Glycart AG Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
BR112015013557B1 (pt) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
WO2014096015A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
SI2945647T1 (sl) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni peptidi WT-1 in postopki za uporabo le-teh
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
WO2014145806A2 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
CA2912514A1 (en) 2013-05-13 2014-11-20 International Institute Of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
AU2014291961B2 (en) 2013-07-19 2018-09-27 Centre Hospitalier Regional Universitaire De Montpellier Targeted modified TNF family members
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
JP6875126B2 (ja) 2014-01-21 2021-05-19 アルバート アインシュタイン カレッジ オブ メディシン 迅速かつ包括的なｔ細胞免疫モニタリング用の細胞プラットフォーム
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
WO2015129790A1 (ja) 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US20170058015A1 (en) * 2014-06-18 2017-03-02 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
EP3180018B1 (en) * 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
RS59939B1 (sr) 2014-08-29 2020-03-31 Hoffmann La Roche Kombinovana terapija il-2 varijantom imunocitokina sa ciljanim delovanjem na tumor i antitelima na humani pd-l1
MY196588A (en) 2015-03-05 2023-04-19 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins and uses Thereof
US20180086832A1 (en) 2015-03-23 2018-03-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
WO2017008844A1 (en) 2015-07-14 2017-01-19 Biontech Ag Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
EP3328377A4 (en) 2015-07-31 2019-03-13 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
CN106565836B (zh) 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
CA3005896C (en) 2015-11-20 2025-09-23 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY MEANS OF THE COMBINATION OF A WT1 PEPTIDE AND A CHECKPOINT INHIBITOR
CA3009799A1 (en) 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particles encapsulating fusion proteins containing linked epitopes
JP2019511458A (ja) 2016-01-27 2019-04-25 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 組み換えＩｇＧ Ｆｃ多量体
WO2017151818A2 (en) 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20190046648A1 (en) 2016-03-03 2019-02-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20250133490A (ko) 2016-05-04 2025-09-05 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN109689096A (zh) * 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
JP2020500015A (ja) 2016-11-09 2020-01-09 ユーティーアイ リミテッド パートナーシップ 組換えｐＭＨＣクラスＩＩ分子
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
EP3446702A1 (en) 2017-08-23 2019-02-27 Medizinische Hochschule Hannover Synthetic vaccine
IL272085B2 (en) 2017-09-07 2023-03-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019051126A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
AU2018328283A1 (en) 2017-09-07 2020-02-20 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
EP3755711A4 (en) 2018-02-20 2021-11-24 Technion Research & Development Foundation Limited IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
WO2020132138A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132135A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132136A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP7691927B2 (ja) 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
EP3935080A4 (en) 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
MX2021014476A (es) 2019-05-29 2022-02-11 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
EP3980051A4 (en) 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
WO2020257191A1 (en) 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20220066075A (ko) 2019-09-20 2022-05-23 큐 바이오파마, 인크. T-세포 조절 폴리펩타이드 및 이의 사용 방법
WO2021081239A1 (en) 2019-10-23 2021-04-29 Cue Biopharma, Inc. T-cell modulatory chimeric molecules and methods of use thereof
JP2023500573A (ja) 2019-10-23 2023-01-10 キュー バイオファーマ， インコーポレイテッド 改変された細胞傷害性ｔ細胞及びその使用方法
CA3163549A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
WO2021127495A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN115176015A (zh) 2020-02-28 2022-10-11 国立大学法人金泽大学 免疫调节法、免疫调节用核酸组合物及其用途
GB202005617D0 (en) 2020-04-17 2020-06-03 Adaptimmune Ltd Improved t cell manufacturing process
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113823723A (zh) 2020-06-18 2021-12-21 光宝光电(常州)有限公司 发光二极管封装结构
AU2021309842A1 (en) 2020-07-14 2023-02-16 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
JP2023553216A (ja) 2020-12-09 2023-12-20 アシャ バイオセラピューティクス，インク． 遺伝子操作細胞療法のための標的化サイトカイン構築物
WO2022125694A1 (en) 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function

Also Published As

Publication number Publication date
EP4431109A2 (en) 2024-09-18
JP2020514375A (ja) 2020-05-21
JP2024026521A (ja) 2024-02-28
CN111010875A (zh) 2020-04-14
CA3054955A1 (en) 2018-09-20
EP3596118A1 (en) 2020-01-22
PH12019502076A1 (en) 2020-10-26
US10927161B2 (en) 2021-02-23
US20230374102A1 (en) 2023-11-23
EP4431109A3 (en) 2024-11-27
WO2018170168A1 (en) 2018-09-20
US20220089681A1 (en) 2022-03-24
KR20190141125A (ko) 2019-12-23
US20200010528A1 (en) 2020-01-09
IL269000B1 (en) 2024-02-01
AU2023251412B2 (en) 2023-12-07
IL269000B2 (en) 2024-06-01
CN118453840A (zh) 2024-08-09
US20200325205A1 (en) 2020-10-15
EP3596118B1 (en) 2024-08-21
IL309479A (en) 2024-02-01
JP2023082126A (ja) 2023-06-13
US20230109980A1 (en) 2023-04-13
KR102619015B1 (ko) 2023-12-28
US11479595B2 (en) 2022-10-25
US20250136660A1 (en) 2025-05-01
US20250145685A1 (en) 2025-05-08
US20240166719A1 (en) 2024-05-23
JP7412622B2 (ja) 2024-01-12
US11104712B2 (en) 2021-08-31
ES2989063T3 (es) 2024-11-25
CN111010875B (zh) 2024-04-05
JP7622193B2 (ja) 2025-01-27
US11993641B2 (en) 2024-05-28
JP7717440B2 (ja) 2025-08-04
AU2023251412A1 (en) 2023-11-09
AU2018234628A1 (en) 2019-09-19
IL269000A (en) 2019-10-31
US20200331982A1 (en) 2020-10-22
KR20240005989A (ko) 2024-01-12
US11958893B2 (en) 2024-04-16
AU2018234628B2 (en) 2023-07-20
EP3596118A4 (en) 2021-04-07
US11767355B2 (en) 2023-09-26
US20210206830A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
SG11201908391XA (en) Methods for modulating an immune response
SG11201808552XA (en) T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201903282TA (en) Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201908478SA (en) Sterilisation method
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201811432WA (en) Rna for cancer therapy
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201809040YA (en) Hybrid aerosol-generating element and method for manufacturing a hybrid aerosol-generating element
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201808306PA (en) Treatment of cancer with tg02
SG11201406625XA (en) Anti-fcrn antibodies
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908512YA (en) Somatostatin modulators and uses thereof